Atricure Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
9analysts covering
FY Revenue (est.)
$606.2Mnext fiscal year
FY EPS (est.)
$0.28next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 27 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Worldwide Revenue Growth Quarterly14.3%Target: 12% to 14% growth for FY 2026 ($600M to $610M)
Adjusted EBITDA Quarterly17.1MTarget: $80M to $82M for FY 2026
Gross Margin Quarterly77.4%Target: Sustained expansion above 75%
Watch Items
- BoxX-NoAF Clinical Trial EnrollmentTrigger: Completion of patient enrollment (960 planned subjects)Action: Monitor for enrollment completion by year-end 2026 (running 12 months ahead of schedule) to set up initial data readout in 2027.
- LeAAPS Clinical Trial Event AccumulationTrigger: Reaching target events for stroke prevention efficacy readoutAction: Track follow-up of the 6,500 enrolled patients; monitor for potential early readout before 2030 as target events surpassed 50% in mid-2026.
- FLEX-Mini and PRO-Mini Adoption in EuropeTrigger: Commercial launch and volume growth in European marketsAction: Assess international revenue contribution following European regulatory approval in spring 2026.
Research as of 20 Jun 2026